Novamind ($NM | $NVMDF | $HN2) is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.
Novamind is focused on three pillars: Clinical care, clinical research and a retreat network
I. Cedar Psychiatry operates four full-service outpatient mental health clinics providing a wide range of innovative treatments:
Administered over 5,000 ketamine treatments since opening in 2016
Over 2,000 Spravato™ treatments administered since the product became available in 2019
Novamind is one of North America’s top providers of ketamine-assisted psychotherapy and Spravato™
II.Cedar Clinical Researchhas significant experience in hosting phase I to IV clinical trials and is a recognized leader in clinical research focused on emerging treatment options in neuropsychiatry including psychedelic medicines
Led Spravato™ trials in Utah for Janssen Pharmaceuticals
Dr. Reid Robison, Novamind’s Chief Medical Officer, is Coordinating Investigator of MAPS’ clinical trial examining MDMA-assisted psychotherapy as a treatment for eating disorders
Developing novel therapeutic protocols that accompany psychedelic-assisted psychotherapy
III. Novamind is building a network of psychedelic retreats in jurisdictions with established regulations for the use of psychedelics and has strategic investments in the Netherlands-based Synthesis Institute and the Costa Rica-based Circadia Center
Synthesis was founded in 2018 and has hosted medically supervised psilocybin retreats for more than 600 participants
Circadia expects to host its first psychedelic retreat post COVID-19
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.